SG Americas Securities LLC Has $473,000 Position in Kronos Bio, Inc. (NASDAQ:KRON)

SG Americas Securities LLC reduced its position in shares of Kronos Bio, Inc. (NASDAQ:KRONGet Rating) by 4.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 141,115 shares of the company’s stock after selling 7,099 shares during the quarter. SG Americas Securities LLC’s holdings in Kronos Bio were worth $473,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also added to or reduced their stakes in the company. Delphia USA Inc. acquired a new stake in Kronos Bio during the 2nd quarter worth approximately $52,000. Privium Fund Management UK Ltd acquired a new position in Kronos Bio in the 2nd quarter valued at $1,566,000. Amalgamated Bank acquired a new position in Kronos Bio in the 1st quarter valued at $35,000. Quantbot Technologies LP raised its holdings in Kronos Bio by 91.1% in the 2nd quarter. Quantbot Technologies LP now owns 12,795 shares of the company’s stock valued at $46,000 after acquiring an additional 6,100 shares in the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in Kronos Bio in the 2nd quarter valued at $41,000. 63.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Piper Sandler dropped their price objective on Kronos Bio from $13.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, November 9th. The Goldman Sachs Group dropped their price objective on Kronos Bio from $25.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, November 10th. Finally, HC Wainwright dropped their price objective on Kronos Bio from $36.00 to $10.00 and set a “buy” rating for the company in a report on Friday, November 18th.

Insider Buying and Selling

In related news, VP Jorge Dimartino sold 18,657 shares of the business’s stock in a transaction on Monday, December 12th. The stock was sold at an average price of $1.81, for a total transaction of $33,769.17. Following the sale, the vice president now owns 219,478 shares in the company, valued at approximately $397,255.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 28.20% of the stock is currently owned by corporate insiders.

Kronos Bio Stock Performance

Shares of KRON opened at $2.31 on Wednesday. Kronos Bio, Inc. has a 52-week low of $1.35 and a 52-week high of $10.62. The business’s fifty day moving average is $1.91 and its 200-day moving average is $3.24. The firm has a market cap of $131.43 million, a price-to-earnings ratio of -0.84 and a beta of 1.08.

Kronos Bio (NASDAQ:KRONGet Rating) last issued its quarterly earnings results on Tuesday, November 8th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.07. As a group, research analysts forecast that Kronos Bio, Inc. will post -2.43 EPS for the current fiscal year.

Kronos Bio Company Profile

(Get Rating)

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients.

Featured Stories

Want to see what other hedge funds are holding KRON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kronos Bio, Inc. (NASDAQ:KRONGet Rating).

Institutional Ownership by Quarter for Kronos Bio (NASDAQ:KRON)

Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.